How to appeal a UnitedHealthcare mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt

Cited policy: UHC Commercial Medical Policy: Mohs Micrographic Surgery (mirrors AAD/ACMS/ASDSA/ASMS Mohs AUC 2012)

AAD/ACMS/ASDSA/ASMS Mohs AUC 2012 score 7-9; Area H location, recurrent tumor, aggressive histologic subtype, ill-defined borders, size threshold, immunosuppression — any of which support appropriateness.

How UnitedHealthcare denies mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt — and how to counter it

Where UnitedHealthcare pushes back: 1) AUC mapping not explicitly cited in op report; 2) 'Standard excision should be used' for Area M/L; 3) Documentation of histologic subtype incomplete.

Counter-arguments that hold up: Map case explicitly to Mohs AUC 2012 Table — anatomic area + histology + size + primary/recurrent + immunostatus = score 7-9 for vast majority of Area H cases. Quote biopsy path subtype verbatim ('infiltrative', 'morpheaform', 'micronodular', 'perineural invasion'). Cite Mosterd Lancet Oncol 2008 + van Loo 2014 — Mohs lower recurrence vs WLE for high-risk BCC at 5- and 10-year.

What UnitedHealthcare typically denies for mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the mohs surgery & dermatologic surgery — bcc, scc, melanoma in situ, slnb, pdt treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Mohs (Area H)
• Mohs (Area M/L per AUC)
• Mohs for melanoma in situ
• Wide local excision (BCC/SCC)
• Wide excision (melanoma)
• SLNB (melanoma)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.